Efficacy of losartan in patients with primary focal segmental glomerulosclerosis resistant to immunosuppressive treatment

Journal of Internal Medicine

Volumn 253, Issue 3, 2003, Pages 329-334

  Usta, M ^a   Ersoy, A ^a   Dilek, Kamil ^a   Ozdemir B ^a   Yavuz, M ^a   Gullulu M ^a   Yurtkuran, M ^a  

^a ULUDAG UNIVERSITY   (Turkey)

Author keywords

Angiotensin receptor blockade; Focal segmental glomerulosclerosis; Losartan; Proteinuria; Treatment resistant

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LOSARTAN; PLASMA PROTEIN; ANTIHYPERTENSIVE AGENT; AZATHIOPRINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; IMMUNOSUPPRESSIVE AGENT;

ADULT; AGE; ALBUMIN BLOOD LEVEL; ARTERIAL PRESSURE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE CLEARANCE; DRUG RESISTANCE; FEMALE; GENDER; GLOMERULOSCLEROSIS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MALE; PRIORITY JOURNAL; PROTEINURIA; BLOOD PRESSURE; DRUG COMBINATION; DRUG EFFECT; FOCAL GLOMERULOSCLEROSIS; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; URINE;

ADRENAL CORTEX HORMONES; ADULT; ANTIHYPERTENSIVE AGENTS; AZATHIOPRINE; BLOOD PRESSURE; CYCLOPHOSPHAMIDE; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; FEMALE; GLOMERULOSCLEROSIS, FOCAL SEGMENTAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LOSARTAN; MALE; PROTEINURIA; TREATMENT OUTCOME;

EID: 0037335776     PISSN: 09546820     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2796.2003.01071.x     Document Type: Article

References (24)

1. Savin VJ, Sharma R, Sharma M et al. Circulating factor associated with increased glomerular permeability to albumin in recurrent focal segmental glomerulosclerosis. N Engl J Med 1996; 334: 878-83.
2. Beaufils H, Alphonse JC, Guedon J, Legrain M. Focal glomerulosclerosis: natural history and treatment. Nephron 1978; 21: 75-85.
3. Cameron JS, Turner DR, Ogg CS, Chantler C, Williams DG. The long-term prognosis of patients with focal segmental glomerulosclerosis. Clin Nephrol 1978; 10: 213-8.
4. Velosa JA, Holley KE, Torres VE, Offord KP. Significance of proteinuria on the outcome of renal function in patients with focal segmental glomerulosclerosis. Mayo Clin Proc 1983; 58: 568-77.
5. Korbet SM, Schwartz MM, Lewis EJ. Primary focal segmental glomerulosclerosis: clinical course and response to therapy. Am J Kidney Dis 1994; 23: 773-83.
6. Rydel JJ, Korbet SM, Borok RZ, Schwartz MM. Focal segmental glomerular sclerosis in adults: presentation, course and response to treatment. Am J Kidney Dis 1995; 25: 534-42.
7. Brown CB, Cameron JS, Turner DR et al. Focal segmental glomerulosclerosis with rapid decline in renal function ('malignant FSGS'). Clin Nephrol 1978; 10; 51-61.
8. Williams JD, Coles GA. Proteinuria - direct cause of renal morbidity? Kidney Int 1994; 45: 443-50.
9. Ponticelli C, Passerini P. Alternative treatments for focal and segmental glomerular sclerosis. Clin Nephrol 2001; 55: 345-8.
10. Prasher PK, Varma PP, Baliga KV. Efficacy of enalapril in the treatment of steroid resistant idiopathic nephritic syndrome. J Assoc Physicians India 1999; 47: 180-2.
11. Gansevoort RT, de Zeeuw D, de Jong PE. Long-term benefits of antiproteinuric effect of angiotensin converting enzyme inhibition on nondiabetic renal disease. Am J Kidney Dis 1993; 22: 202-6.
12. Usta M, Dilek K, Yavuz M, Ersoy A, Gullulu M, Yurtkuran M. Anti-proteinuric effect of angiotensin II receptor antagonist losartan in cases with glomerular lesions. Clin Nephrol 2001; 55: 260-2.
13. Praga M, Hernandes E, Montoyo C, Andres A, Ruilope LM, Rodicio JL. Long term beneficial effects of angiotensin converting enzyme inhibition in patients with nephritic proteinuria. Am J Kidney Dis 1992; 20: 240-8.
14. Kon V, Fogo A, Ichikawa I. Bradykinin causes selective efferent arteriolar dilation during angiotensin I converting enzyme inhibition. Kidney Int 1993; 44: 545-50.
15. Burdmann EA, Andoh TF, Nast CC et al. Prevention of experimental cyclosporin-induced interstitial fibrosis by losartan and enalapril. Am J Physiol 1995; 269: F491-F499.
16. Wu LL, Cox A, Roe CJ, Dziadek M, Cooper ME, Gilbert RE. Transforming growth factor beta 1 and renal injury following subtotal nephrectomy in the rat: role of the renin-angiotensin system. Kidney Int 1997; 51: 1553-67.
17. 1 receptor inhibition on chemoattractant and adhesion molecule synthesis. Am J Physiol 1998; 274: F580-F586.
18. Ots M, Mackenzie HS, Troy JL, Rennke HG, Brenner BM. Effects of combination therapy with enalapril and losartan on the rate to progression of renal injury with 5/6 renal ablation. J Am Soc Nephrol 1998; 9: 224-30.
19. Crenshaw G, Bigler S, Salem M, Crook ED. Focal segmental glomerulosclerosis in African Americans: effects of steroids and angiotensin converting enzyme inhibitors. Am J Med Sci 2000; 319: 320-5.
20. Ruggenenti P, Perna A, Mosconi L et al. Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non diabetic nephropathy. Lancet 1997; 349: 1857-63.
21. Ruggenenti P, Perna A, Gherardi G, Gaspari F, Benini R, Remuzzi G. Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Ramipril Efficacy in Nephropathy. Lancet 1998; 352: 1252-6.
22. Lewis EJ, Hunsicker LG, Clarke WR et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Eng J Med 2001; 345: 851-60.
23. Brenner BM, Cooper ME, de Zeeuw D et al. RENAAL Study Investigators: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Eng J Med 2001; 345: 861-9.
24. Bidani AK, Griffin KA, Bakris G, Picken MM. Lack of evidence of blood pressure-independent protection by renin-angiotensin system blockade after renal ablation. Kidney Int 2000; 57: 1651-61.